{
  "abstract": "stop TRIO without switching (8.8%); and death on TRIO (7.2%). Conclusions: Although the most common outcome after TRIO was switch to another three or more drug regimen, almost one third of virologically suppressed PWH under TRIO (with a history of multidrug resistance) switched to a drug-reducing regimen, the majority of whom maintained suppression.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 19,
  "authors": [
    {
      "name": "Suzanne M Ingle"
    },
    {
      "name": "Fabrice Bonnet"
    },
    {
      "name": "Linda Wittkop"
    },
    {
      "name": "Alexandra Calmy"
    },
    {
      "name": "Ramon Teira"
    },
    {
      "name": "Peter F Rebeiro"
    },
    {
      "name": "Heidi M Crane"
    },
    {
      "name": "Christoph Stephan"
    },
    {
      "name": "Marc van der Valk"
    },
    {
      "name": "Christoph Boesecke"
    },
    {
      "name": "Giota Touloumi"
    },
    {
      "name": "M. John Gill"
    },
    {
      "name": "Katharina Grabmeier-Pfistershammer"
    },
    {
      "name": "Federico Garcia"
    },
    {
      "name": "Francesca Ceccherini-Silberstein"
    },
    {
      "name": "Greer Burkholder"
    },
    {
      "name": "Adam Trickey"
    },
    {
      "name": "Jonathan a C Sterne"
    },
    {
      "name": "Mojgan Hessamfar"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/by3s5dms9vr61.bib",
  "cited_by": 0,
  "doi": "10.1016/j.ijantimicag.2026.107925",
  "fulltext_url": null,
  "id": "by3s5dms9vr61",
  "issns": [
    "0924-8579",
    "1872-7913"
  ],
  "landing_url": "https://hal.science/hal-05737404v1",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.spee"
    ],
    [
      "openalex",
      "2725|HIV/AIDS drug development and treatment"
    ]
  ],
  "openalex": "W7168210671",
  "pdf_url": "https://hal.science/hal-05737404/document",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-03",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/by3s5dms9vr61.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:27Z",
      "native_id": "hal-05737404",
      "source": "hal",
      "url": "https://hal.science/hal-05737404v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:0.sdv",
      "subfield": "general"
    },
    {
      "field": "medicine",
      "origin": "hal:1.sdv.spee",
      "subfield": "epidemiology-public-health"
    }
  ],
  "title": "Outcomes for persons with triple-class resistant HIV and a history of virologic failure",
  "title_text": "Outcomes for persons with triple-class resistant HIV and a history of virologic failure",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:27Z",
  "url": "https://research.draconitic.com/paper/by3s5dms9vr61",
  "venue": "International Journal of Antimicrobial Agents",
  "versions": []
}